High mortality within 90 days of diagnosis in patients with Cushing’s syndrome: results from the ERCUSYN registry
-
- Elena Valassi
- 1IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain
-
- Antoine Tabarin
- 2Department of Endocrinology, Diabetes and Nutrition, University of Bordeaux, Bordeaux, France
-
- Thierry Brue
- 3Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale INSERM U1251, Marseille Medical Genetics, Marseille, France and Assistance Publique Hôpitaux de Marseille (APHM), Hôpital de la Conception, Marseille, France
-
- Richard A Feelders
- 4Erasmus University Medical Centre, Rotterdam, The Netherlands
-
- Martin Reincke
- 5Medizinische Klinik und Poliklinik IV, Campus Innestadt, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
-
- Romana Netea-Maier
- 6Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
-
- Miklós Tóth
- 72nd Department of Medicine, Semmelweis University, Budapest, Hungary
-
- Sabina Zacharieva
- 8Medical University of Sofia, Sofia, Bulgary
-
- Susan M Webb
- 1IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain
-
- Stylianos Tsagarakis
- 9Athens Polyclinic General Hospital & Evangelismos Hospital, Athens, Greece
-
- Philippe Chanson
- 10Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le Kremlin Bicêtre, Paris, France
-
- Marija Pfeiffer
- 13Klinicni Center, Ljubljana, Slovenia
-
- Michael Droste
- 14Praxis für Endokrinologie Droste, Oldenburg, Germany
-
- Irina Komerdus
- 15Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russia
-
- Darko Kastelan
- 16Department of Endocrinology, University Hospital Zagreb, Zagreb, Croatia
-
- Dominique Maiter
- 17UCL Cliniques Universitaires St Luc, Brussels, Belgium
-
- Olivier Chabre
- 18Hospitalier Universitaire, Grenoble, France
-
- Holger Franz
- 19Lohmann & Birkner Health Care Consulting GmbH, Berlin, Germany
-
- Alicia Santos
- 1IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain
-
- Christian J Strasburger
- 20Division of Clinical Endocrinology, Department of Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany
-
- Peter J Trainer
- 21Department of Endocrinology, Christie Hospital, Manchester, UK
-
- John Newell-Price
- 22Academic Unit of Diabetes, Endocrinology and Reproduction, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK
-
- Oskar Ragnarsson
- 23Institute of Medicine at Sahlgrenska Academy, University of Gothenburg and the Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
この論文をさがす
説明
<jats:sec> <jats:title>Objective</jats:title> <jats:p>Patients with Cushing’s syndrome (CS) have increased mortality. The aim of this study was to evaluate the causes and time of death in a large cohort of patients with CS and to establish factors associated with increased mortality.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>In this cohort study, we analyzed 1564 patients included in the European Registry on CS (ERCUSYN); 1045 (67%) had pituitary-dependent CS, 385 (25%) adrenal-dependent CS, 89 (5%) had an ectopic source and 45 (3%) other causes. The median (IQR) overall follow-up time in ERCUSYN was 2.7 (1.2–5.5) years.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Forty-nine patients had died at the time of the analysis; 23 (47%) with pituitary-dependent CS, 6 (12%) with adrenal-dependent CS, 18 (37%) with ectopic CS and two (4%) with CS due to other causes. Of 42 patients whose cause of death was known, 15 (36%) died due to progression of the underlying disease, 13 (31%) due to infections, 7 (17%) due to cardiovascular or cerebrovascular disease and 2 due to pulmonary embolism. The commonest cause of death in patients with pituitary-dependent CS and adrenal-dependent CS were infectious diseases (<jats:italic>n</jats:italic> = 8) and progression of the underlying tumor (<jats:italic>n</jats:italic> = 10) in patients with ectopic CS. Patients who had died were older and more often males, and had more frequently muscle weakness, diabetes mellitus and ectopic CS, compared to survivors. Of 49 deceased patients, 22 (45%) died within 90 days from start of treatment and 5 (10%) before any treatment was given. The commonest cause of deaths in these 27 patients were infections (<jats:italic>n</jats:italic> = 10; 37%). In a regression analysis, age, ectopic CS and active disease were independently associated with overall death before and within 90 days from the start of treatment.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Mortality rate was highest in patients with ectopic CS. Infectious diseases were the commonest cause of death soon after diagnosis, emphasizing the need for careful clinical vigilance at that time, especially in patients presenting with concomitant diabetes mellitus.</jats:p> </jats:sec>
収録刊行物
-
- European Journal of Endocrinology
-
European Journal of Endocrinology 181 (5), 461-472, 2019-11
Oxford University Press (OUP)